Aciont gets grant for macular degeneration study

The NIH and the National Eye Institute are backing new research to determine if a non-invasive technology can be used to deliver Avastin and Lucentis as a treatment for age-related macular degeneration. Aciont will use the $214,000 grant to study delivering the therapies with the Visulex ocular application. Release

Suggested Articles

Rutgers scientists have developed an anti-inflammatory drug delivery platform to better treat central nervous system injuries and disease.

Purdue's reformulated OxyContin may stop patients from snorting or injecting the drug, but it doesn't curb abuse overall, an FDA panel determined.

Roche is gearing up to launch an eye implant to make its Lucentis AMD drug easier to use. But the drugmaker has even bigger plans for the device.